Abstract:Background: Immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) have become increasingly available for multiple types of cancers, although the cardiovascular safety profiles of this combination therapy in real-world settings have not been elucidated to date. Therefore, we aimed to comprehensively investigate the cardiovascular toxicity profiles of ICIs combined with AGIs in comparison with ICIs alone. Methods: The Food and Drug Administration Adverse Event Reporting System (FAERS) database from the 1 st quarter of 2014 to the 1 st quarter of 2022 was retrospectively queried to extract reports of cardiovascular adverse events (AEs) associated with ICIs alone, AGIs alone and combination therapy. To perform disproportionality analysis, the reporting odds ratios (RORs) and information components (ICs) were calculated with statistical shrinkage transformation formulas and a lower limit of the 95% confidence interval (CI) for ROR (ROR 025 ) > 1 or IC (IC 025 ) > 0 with at least 3 reports was considered statistically significant. Results: A total of 18 854 cardiovascular AE cases/26 059 reports for ICIs alone, 47 168 cases/67 595 reports for AGIs alone, and 3 978 cases/5 263 reports for combination therapy were extracted. Compared to the entire database of patients without AGIs or ICIs, cardiovascular AEs were overreported in patients with combination therapy (IC 025 /ROR 025 = 0.559/1.478), showing stronger signal strength than those taking ICIs alone (IC 025 /ROR 025 = 0.118/1.086) or AGIs alone (IC 025 /ROR 025 = 0.323/1.252). Importantly, compared with ICIs alone, combination therapy showed a decrease in signal strength for noninfectious myocarditis/pericarditis (IC 025 /ROR 025 = 1.142/2.216 vs . IC 025 /ROR 025 = 0.673/1.614), while an increase in signal value for embolic and thrombotic events (IC 025 /ROR 025 = 0.147/1.111 vs . IC 025 /ROR 025 = 0.591/1.519). For outcomes of cardiovascular AEs, the frequency of death and life-threatening AEs was lower for combination therapy than ICIs alone in noninfectious myocarditis/pericarditis (37.7% vs . 49.2%) as well as in embolic and thrombotic events (29.9% vs . 39.6%). Analysis among indications of cancer showed similar findings. Conclusion: Overall, ICIs combined with AGIs showed a greater risk of cardiovascular AEs than ICIs alone, mainly due to an increase in embolic and thrombotic events while a decrease in noninfectious myocarditis/pericarditis. In addition, compared with ICIs alone, combination therapy presented a lower frequency of death and life-threatening in noninfectious myocarditis/pericarditis and embolic and thrombotic events.

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022

Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022)

Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis

Immune-related interstitial lung disease adverse event following immune checkpoint inhibitors and immune checkpoint inhibitors plus anti-VEGF antibody/chemotherapy: A real-world study from 2014 to 2022 based on FAERS databases

Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis

Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS

Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials

Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis

Association among major adverse cardiovascular events with immune checkpoint inhibitors: A systematic review and meta‐analysis

Adverse Reactions Associated With Immune Checkpoint Inhibitors and Bevacizumab: A Pharmacovigilance Analysis

Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system

Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database

Cardiovascular and venous thromboembolism risks in cancer patients treated with immune checkpoint inhibitors compared to non-users- a multi-center retrospective study

Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database

Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system

Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies

Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system